Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2022

View Archived Issues

NiKang Therapeutics patents new PROTACs for cancer

Genzyme discloses new CSF-1R inhibitors

Gilead Sciences synthesizes new PADI4 inhibitors

University of California presents new CYP3A4 inhibitors

MEKanistic Therapeutics identifies new PI3K and/or EGFR inhibitors

GATA1 c.616A>C mutation tied to thrombocytopenia due to platelet formation impairment

Inosine released by apoptotic brown adipocytes regulates thermogenic fat and counteracts obesity

PAN domain regulates binding and activation of the c-MET pathway and may be an anticancer target

Novel variants in genes HPS3, HPS5 and DTNBP1 linked to Hermansky-Pudlak syndrome

Preclinical characterization of novel antileishmanial agents

PharmaCyte begins pig study to support planned clinical trial of CypCaps for pancreatic cancer

FDA clears IND for Obsidian's TIL therapy OBX-115

Sosei and Cancer Research UK agree to advance EP4 antagonist HTL-0039732 into clinic

Oncogenic collagen allows cancer cells to evade immune response

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...